cooperative interactions between variants in a viral population. We previously described two 26 distinct variants of H3N2 influenza virus that cooperate in cell culture. These variants differ by a 27 single mutation, D151G, in the neuraminidase protein. The D151G mutation reaches a stable 28 frequency of about 50% when virus is passaged in cell culture. However, it is unclear whether 29 selection for the cooperative benefits of D151G is a cell-culture phenomenon, or whether the 30 mutation is also sometimes present at appreciable frequency in virus populations sampled 31 directly from infected humans. Prior work has not detected D151G in unpassaged clinical 32
samples, but these studies have used methods like Sanger sequencing and pyrosequencing 33 that are relatively insensitive to low-frequency variation. We identified nine samples of human 34
H3N2 influenza collected between 2013 to 2015 in which Sanger sequencing had detected a 35 high frequency of the D151G mutation following one to three passages in cell culture. We deep-36 sequenced the unpassaged clinical samples to identify low-frequency viral variants. The 37 frequency of D151G did not exceed the frequency of library preparation and sequencing errors 38 in any of the sequenced samples. We conclude that passage in cell culture is primarily 39 responsible for the frequent observations of D151G in recent H3N2 influenza strains. 40 41 IMPORTANCE 42 43
Viruses mutate rapidly, and recent studies of RNA viruses have shown that related viral variants 44
can sometimes cooperate to improve each other's growth. We previously described two variants 45 of H3N2 influenza virus that cooperate in cell culture. The mutation responsible for cooperation 46
is often observed when human samples of influenza virus are grown in the lab before 47
sequencing, but it is unclear whether the mutation also exists in human infections or is 48 exclusively the result of lab passage. We identified nine human isolates of influenza that had 49 developed the cooperating mutation after being grown in the lab, and performed highly sensitive 50
deep-sequencing of the unpassaged clinical samples to determine whether the mutation existed 51 in the original human infections. We found no evidence of the cooperating mutation in the 52 unpassaged samples, suggesting that the cooperation primarily arises in laboratory conditions. 53 54 INTRODUCTION 55 56
RNA viruses like influenza mutate rapidly to form genetically diverse quasispecies. Several 57 recent studies have suggested that interactions between different variants in a quasispecies can 58 promote overall population fitness. In poliovirus, variants generated through spontaneous 59 mutation are important for neurotropism, innate immune suppression, and overall pathogenesis 60 in mouse models (1-3). Other groups have identified cooperative interactions in measles virus 61
(4), West Nile virus (5), hepatitis B virus (6), and Coxsackie virus (7). These cooperative 62
interactions have primarily been observed in cell culture or animal models rather than clinical 63
infections. 64 65
We previously described two distinct variants of H3N2 influenza virus that cooperate in cell 66
culture (8). The two variants differ by a single mutation at amino acid 151 of neuraminidase 67 (NA), the protein that releases new virions from host cells. The D151 viral variant, typically 68 encoded as GAT, predominates among clinical influenza samples, and it grows robustly in cell 69
culture. The G151 viral variant, typically encoded as GGT, binds sialic-acid receptors rather than 70 cleaving them (9, 10) and grows extremely poorly in isolation. However, a mixed population of 71 D151 and G151 viral variants outgrows either single variant in cell culture.
73
An important question is whether cooperation between these two viral variants is purely a cell-74 culture phenomenon, or whether the D151 and G151 variants co-exist in natural infections. The 75 D151G mutation is frequently observed when influenza virus is passaged through cell culture (9, 76 11-16), but it remains unclear whether the G151 variant exists within natural human infections 77
or is primarily a cell-culture artifact. Prior groups that have performed matched clinical 78 sequencing of unpassaged and passaged clinical samples have failed to detect the G151 79 variant before passaging (13, 15), but these studies have used methods like Sanger sequencing 80
and pyrosequencing that are relatively insensitive to rare variation. More sensitive 81 characterization of clinical samples that give rise to D151G upon lab passage can determine 82 whether this mutation reaches high frequencies in cell culture because it is amplified from low-83
to modest-frequency standing diversity, or whether it arises spontaneously in the lab. 84 85
We sought to determine whether the D151G mutation is present in viral populations isolated 86 from natural human infections. We identified nine clinical samples that, based on prior Sanger 87 sequencing, consisted of a mixture of D151 and G151 viruses after passage in cell culture. We 88 deep-sequenced the original unpassaged nasal swab samples to survey the variation present 89
prior to laboratory growth. The D151G mutation did not exceed the frequency of library 90 preparation and sequencing errors in any of these samples. These results suggest that most 91 variation observed at site 151 results from passage in cell culture rather than standing variation 92 in human infections. 93 94 RESULTS 95 96
Most influenza-virus sequences in public databases are determined by Sanger sequencing of 97 clinical isolates that have been passaged one or more times in cell culture (17). A substantial 98
number of recent human H3N2 influenza virus sequences in these databases contain an 99 ambiguous nucleotide at NA site 151 because the lab-passaged samples often converge to a 100 mix of the D151 and G151 variants (8). We sought to compare passaged samples that 101 contained this ambiguous nucleotide at site 151 to unpassaged samples from the same viral 102 infections. We first identified strains from western Washington state in the GISAID EpiFlu 103 database (18) for which Sanger sequencing had reported an ambiguous nucleotide at NA site 104 151 corresponding to a mix of the D151 and G151 variants (8). Based on the annotations 105 available in the GISAID EpiFlu database, most of these strains had been passaged in cell 106 culture prior to Sanger sequencing. 107 108
We obtained original, unpassaged nasal swab samples for the nine strains in Table 1 that 109 contained a mixture of D151 and G151 variants after passage in cell culture. These samples 110
had been collected between 2013 and 2015 and had undergone one to three passages in cell 111 culture prior to sequencing. We performed whole-genome sequencing of the influenza genome 112 from the unpassaged clinical samples using influenza-specific reverse transcription and PCR 113 (19) . For each sample, we prepared sequencing libraries in duplicate, beginning from separate 114
reverse-transcription reactions (20). We sequenced each viral sample to an average 115 sequencing depth of 100x-10,000x (Figure 1) , allowing us to observe viral variants at 116
frequencies below the limit of detection of Sanger sequencing or pyrosequencing. 117 118
We identified all minor viral variants present at a frequency of at least 3% in the viral genome in 119 both library replicates ( Table 2) . We did not observe the D151G variant in any of the nine 120
clinical samples under these variant-calling criteria. To ensure that we were not missing 121 extremely low-frequency variation, we calculated the frequency of D151G in each clinical 122 sample based on the frequency of G-to-A mutations at the second nucleotide position of NA site 123 151. We compared this frequency to the frequency of G-to-A mutations at other sites across the 124 genome (Figure 2) . Minor-variant frequencies at NA site 151 fell well within the range of error 125 expected through library preparation and sequencing errors. Therefore, we conclude that the 126 D151G variant was not present at appreciable frequencies in the original clinical infections. 127
Instead, the mutation must have arisen de novo or been enriched from an extremely low 128 frequency during passage in cell culture. 129 130 DISCUSSION 131 132
The results of our deep-sequencing study support prior studies that failed to detect the D151G 133 mutation in unpassaged clinical samples using Sanger sequencing or pyrosequencing methods 134 (13, 15) . In the GISAID EpiFlu database, mixed populations of D151 and G151 viral variants are 135 common in clinical samples that have been passaged in cell culture, but these mixed 136
populations are rare among unpassaged and egg-passaged populations (8). It is impossible to 137 rule out the possibility that the D151G mutation reaches appreciable frequencies in some 138 natural human infections, but strong and repeated selection for cooperation in cell culture 139 seems to account for its prevalence among sequences in public databases. 140 141
It is interesting to speculate about what biological factors might cause a variant that is rare in 142
natural human infections to be strongly selected in cell culture. Influenza strains often acquire 143 stereotypical mutations when they are grown in eggs (21, 22), but these passage adaptations 144
appear to be less common in cell culture, particularly for MDCK-SIAT1 cells (17, 23) . 145
Nevertheless, differences in the types and distributions of cell-surface receptors between 146
MDCK-SIAT1 cells and human airways could account for some of the differences in genotypes 147
we observe at NA site 151. 148 149
We also previously observed that cooperation is stronger at high multiplicities of infection (MOI) 150 (8). Viral load can be high during natural infections ( Table 1) , but recent studies of natural 151
human infections have found that the effective reassortment rate is limited, suggesting that 152 spatial heterogeneity within the host may limit viral circulation and co-infection (24). Moreover, 153 human influenza infections, as well as those in animal models (25) Mini Kit (Qiagen) according to manufacturer's instructions. We reverse-transcribed the viral RNA 183
using the Superscript III First-Strand Reaction Mix (Thermo Fisher) and an equimolar mix of the 184 influenza-specific primers 185 5'-TATTGGTCTCAGGGAGCAAAAGCAGG-3' and 5'-TATTGGTCTCAGGGAGCGAAAGCAGG-186
3', which both bind to the conserved U12 region at one end of each influenza gene. The two 187 primers differ by a single nucleotide to account for a known polymorphism in the region. We 188 incubated the reverse-transcription reactions at 25 degrees C for 10 minutes (to help the short 189 primer anneal), 50 degrees C for 50 minutes, and 85 degrees C for 5 minutes. We amplified the 190 influenza genome using a mixture of 24 primers that bind to the ends of each influenza gene 191 (31). For each gene, one primer binds to the conserved U13 region at one end of the gene, and 192 two primers bind to the conserved U12 region at the other end of the gene, allowing for the 193 known polymorphism in the U12 region. We performed 35 cycles of PCR using an annealing 194 temperature of 55 degrees C and an extension time of 3 minutes. We purified the PCR product 195 using 1X AMPure beads (Beckman Coulter) and prepared libraries for Illumina sequencing 196
using Nextera XT (Illumina) tagmentation. We sequenced the libraries on a NextSeq 500 197 platform (Illumina) with 150 bp paired-end reads. We performed all library preparation and 198 sequencing in duplicate, starting from independent reverse-transcription reactions (20).
200
Analysis of deep-sequencing data. We first used bowtie2 (32) to filter out reads that mapped 201
to the human genome. Remaining reads are available in the SRA as BioProject PRJNA412675.
202
We trimmed adapters from the raw reads using cutadapt version 1.8.3 (33). We first aligned the 203 reads to the A/Victoria/361/2011 genome using bowtie2 and the --very-sensitive setting, 204 then we used custom scripts to generate a new consensus genome sequence for each viral 205 sample. We then re-aligned the reads to the corresponding consensus sequence and removed 206 PCR duplicates using picard version 1.43. We used custom scripts to filter out base calls with a 207 quality score below 20, tally the total number of high-quality bases at each genome position, 208
and annotate each variant's codon position. We performed these initial analyses separately for 209 each replicate library. We reported only variants that were located in protein-coding sequence. 210 211
A note on codon numbering and gene annotation 212
We numbered HA codons according to the H3 encoded by the nucleotides GAT, and the G151 variant is encoded as GGT, meaning that D151G 361 arises as the result of a G-to-A mutation. The red vertical line shows the proportion of G-to-A 362 mutations at codon position 2 of amino-acid site 151 of NA, which corresponds to the frequency 363 of D151G. In cases where no G-to-A mutations were identified at this site, this red line is not 364
shown. At each nucleotide site in the genome with consensus identity G, we calculated the total 365
proportion of reads reporting an identity of A at that site and averaged this proportion between 366 both replicate libraries. As expected, G-to-A mutations make up less than 0.1% of total 367
sequencing reads at most sites in the genome and are probably errors introduced through 368 library preparation and sequencing. 369
